Our Expertise

Market Access

We design and execute market access strategies that ensure innovative technologies are positioned for optimal coverage and payment — across commercial payers, Medicare, and Medicaid — from early development through full commercialization. As medical device reimbursement consultants, we turn regulatory milestones into a clear path to coverage, coding, and payment.

Who We Serve
From conception to commercialization

For novel technology companies, established device manufacturers, and conception-stage innovators alike, our market access work addresses the full continuum: coding, coverage, payment, pricing, and long-term commercial viability.

We bring clinical fluency and payer intelligence together to build strategies that are rigorous, audit-ready, and grounded in how care is actually delivered and reimbursed.

What We Do
Our Market Access Capabilities
07 Capabilities
01

Coding Assessment


Determining whether existing codes apply to your technology, identifying gaps, and defining the pathway to new coding where needed.

02

Coverage & Reimbursement Strategy


Building the roadmap for public and private payer coverage across care settings, including outpatient, physician, and facility environments.

03

Coding & Payment Pathway Design


Navigating the full reimbursement landscape for novel and existing technologies, including code qualification, application, and billing validation.

04

Payer Engagement & Policy Monitoring


Tracking health policy and market intelligence that affect your coverage position, while staying current on evolving private payer policies on an ongoing basis.

05

New Technology Add-on Payment (NTAP)


Assessing NTAP eligibility under the newness, cost, and substantial clinical improvement criteria, including transition eligibility for Breakthrough Devices designated by September 30, 2026, and preparing applications that make the case for additional inpatient payment, so hospitals can adopt new technology with financial confidence.

06

Pricing Strategy & Market Adoption Analysis


Integrating pricing directly into your reimbursement strategy — including value analysis committee framing, pricing modeling, and ROI analysis grounded in your reimbursement pathway assessment.

Prevara guides clients through the coding and reimbursement process. We do not provide billing services on behalf of providers.

FAQ

Medical Device Reimbursement: Frequently Asked Questions

When should a medical device company start planning for reimbursement?

Earlier than most companies expect, ideally while you are still designing your clinical studies. Payers, including Medicare, look for evidence that a technology improves outcomes for their specific patient population, and that evidence is far easier to build into a pivotal trial than to add after FDA authorization.

Planning early also gives you time to assess coding, identify the right care setting, and set a price the reimbursement landscape can support.

What is the difference between coding, coverage, and payment?

They are three separate hurdles, and a technology needs all three to be reimbursed. Coding describes the service so it can be billed, using systems like CPT, HCPCS, and ICD-10-PCS. Coverage is a payer's decision that the service is reasonable and necessary, set through national or local coverage determinations for Medicare and through medical coverage policies for commercial payers. Payment is the amount the payer pays, set by fee schedules and payment systems that vary by care setting and payer.

A gap in any one of the three can stall new technology adoption, which is why we assess them together rather than one at a time.

Does FDA clearance or approval mean Medicare will cover my device?

No. FDA and CMS apply different standards. FDA decides whether a device is safe and effective, while Medicare decides whether it is reasonable and necessary for Medicare beneficiaries, who are often older and more medically complex than the patients in a typical pivotal trial.

Many devices reach the market with FDA authorization but no clear path to coverage. That is why coverage strategy should run alongside regulatory strategy rather than after it.

What pathways exist to get Medicare coverage and payment for a new technology?

Several Medicare pathways can help a new technology bridge the gap between FDA authorization and established coverage and payment. The right one depends on the technology, its evidence, and the care setting where it is used.

For coverage, a manufacturer can request a National Coverage Determination, work with Medicare Administrative Contractors on Local Coverage Determinations, or pursue claim-by-claim review. CMS has also proposed the RAPID pathway, which would let eligible Breakthrough Devices receive a proposed national coverage decision the same day FDA authorizes them. CMS has paused new candidates for its earlier TCET pathway while it builds RAPID.

For payment, New Technology Add-on Payments (NTAP) support new technologies in the hospital inpatient setting, while transitional pass-through payments and New Technology APCs play a similar role in the hospital outpatient setting. Category III CPT codes can also give emerging services a way to be billed before they qualify for a permanent code.

Most technologies need a combination of these, which is why we map coding, coverage, and payment together from the start.

What is NTAP, and does my technology qualify?

The New Technology Add-on Payment (NTAP) is an additional Medicare payment to hospitals for inpatient cases that use a qualifying new technology, helping offset its cost while standard payment rates catch up. To qualify, a technology generally must be new, meet a cost threshold, and represent a substantial clinical improvement over existing options.

CMS has ended the alternative pathway that exempted FDA Breakthrough Devices from the clinical improvement test for new applications, apart from a limited transition window, so the strength of your clinical evidence now matters more than ever. Read our analysis of the NTAP change.

Does my technology need a new CPT code?

Not always. The first step is a coding assessment to determine whether existing codes accurately describe your technology and support appropriate payment.

If they don't, there are several routes. Category I CPT codes generally require FDA clearance or approval, use by many physicians, and published clinical evidence. Category III codes track emerging technologies that don't yet meet those criteria. HCPCS Level II codes can apply to certain devices and supplies. New codes often take more than a year to obtain, so it pays to start the assessment early.

How is reimbursement different for SaMD and AI-enabled software?

Software-based technologies face distinct questions about how to describe the service, which care setting pays for it, and how to value it. Medicare is building a dedicated framework: for 2027, CMS finalized the term "Software as a Medical Service" for algorithm-based services that support clinical decision-making, and is assigning these services to New Technology APCs in the hospital outpatient setting while a broader payment policy develops.

Read our analysis of the CY 2027 Physician Fee Schedule for what this means for AI and SaMD companies.

Does Prevara provide billing services?

No. Prevara guides clients through the coding and reimbursement process, from strategy through code applications and payer engagement. We do not submit claims or provide billing services on behalf of providers.

Work With Us

Ready to build your market access strategy?

Let's talk about where your technology is in development and how Prevara can help you get to market.

Get In Touch →